Interpace Diagnostics Group, Inc.
(NASDAQ : IDXG)

( )
IDXG After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
LHLaboratory Corporation of America Holdings
-1.52%135.612.3%$131.19m
CERNCerner Corporation
-2.00%52.987.5%$107.80m
DGXQuest Diagnostics Incorporated
-1.00%86.174.2%$101.43m
ATHNathenahealth, Inc.
0.03%133.8717.4%$82.55m
SRCLStericycle, Inc.
0.65%42.046.3%$42.78m
MDRXAllscripts Healthcare Solutions, Inc.
-1.15%12.059.7%$30.22m
HCSGHealthcare Services Group, Inc.
0.64%44.066.7%$20.14m
OMCLOmnicell, Inc.
-3.27%65.4010.9%$17.13m
HMSYHMS Holdings Corp.
-2.43%28.861.9%$15.88m
CPSIComputer Programs and Systems, Inc.
-1.33%26.6932.9%$2.74m
HSTMHealthStream, Inc.
-1.43%24.906.7%$1.94m
PMDPsychemedics Corporation
-2.70%17.640.7%$0.26m
PLXProtalix Biotherapeutics, Inc.
-4.06%0.415.8%$0.22m
IDXGInterpace Diagnostics Group, Inc.
-4.63%1.033.3%$0.19m
STRMStreamline Health Solutions, Inc.
-4.72%1.210.3%$0.04m

Company Profile

Interpace Diagnostics Group, Inc. is an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.